Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells

Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia (CML), but the frequency of resistance increases in advancing stages of disease. Elimination of BCR/ABL-dependent intracellular signals trigger...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bellodi, Cristian, Lidonnici, Maria Rosa, Hamilton, Ashley, Helgason, G. Vignir, Soliera, Angela Rachele, Ronchetti, Mattia, Galavotti, Sara, Young, Kenneth W., Selmi, Tommaso, Yacobi, Rinat, Van Etten, Richard A., Donato, Nick, Hunter, Ann, Dinsdale, David, Tirrò, Elena, Vigneri, Paolo, Nicotera, Pierluigi, Dyer, Martin J., Holyoake, Tessa, Salomoni, Paolo, Calabretta, Bruno
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2673867/
https://ncbi.nlm.nih.gov/pubmed/19363292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI35660
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados